United Therapeutics (UTHR 1.79%) has once again received a rejection from the FDA for its oral Remodulin for pulmonary arterial hypertension. In this video, Motley Fool health-care analyst David Williamson tells investors why this resubmission may have been too soon, what the company would need to do before the next resubmission to have a chance at approval, and who the hidden losers are in this rejection.
United Therapeutics Can't Stop Getting Rejected
By Dave Williamson – Mar 25, 2013 at 8:03PM
NASDAQ: UTHR
United Therapeutics
Market Cap
$19B
Today's Change
(-1.79%) $7.63
Current Price
$418.58
Price as of October 24, 2025 at 4:00 PM ET
Another FDA rejection for United Therapeutics?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid